基于C反应蛋白新炎症因子组合在结直肠癌诊断中的临床价值
Clinical Value of Novel Inflammatory Factor Combinations Based on C-Reactive Protein in the Diagnosis of Colorectal Cancer
DOI: 10.12677/acm.2025.1592501, PDF, HTML, XML,    科研立项经费支持
作者: 苏友玉, 徐大方*, 郑思洋, 胡 洁:湖州师范学院附属第一医院普通外科,浙江 湖州;石 茜:湖州师范学院附属第一医院中心实验室,浙江 湖州;强 锋:湖州师范学院附属第一医院消化内科,浙江 湖州
关键词: 淋巴细胞/C反应蛋白比值(LCR)C反应蛋白/白蛋白比值(CAR)CA199CEA结直肠癌Lymphocyte/C-Reactive Protein Ratio (LCR) C-Reactive Protein/Albumin Ratio (CAR) CA199 CEA Colorectal Cancer
摘要: 目的:探讨基于C反应蛋白为基础的新炎症因子组合LCR、CAR及CA199、CEA等指标在结直肠癌临床诊断中的价值。方法:将2020年04月至2023年04月在本院手术治疗的结直肠癌患者163例设置为结直肠癌组,93例结直肠息肉组为对照组。通过比较淋巴细胞/C反应蛋白比值(LCR)、C反应蛋白/白蛋白比值(CAR),CA199及CEA在两组中的差异,与临床病理特征关联分析,ROC曲线绘制检测结果。结果:结直肠癌组中CAR、CEA、CA199表达明显增高,LCR表达下降,各组存在统计学差异(P < 0.001)。LCR在肿瘤浸润深度(T3 + T4)组表达明显低于(T1 + T2)组,有淋巴结转移组表达降低,TNM分期为(III + IV)表达明显低于(I + II)组,各组之间均有统计学差异。而CAR、CEA、CA199表达与LCR相反,各组统计学差异明显(P < 0.05)。ROC提示联合诊断敏感度为56.4%,特异性为90.3%。结论:LCR、CAR、CA199、CEA水平与结直肠癌患者的临床病理特征相关,对结直肠癌的诊断有潜在价值,联合检测能提高对结直肠癌诊断的特异度。
Abstract: Objective: Exploring the value of new inflammatory factor combinations based on C-reactive protein, such as LCR, CAR, CA199, CEA in the clinical diagnosis of colorectal cancer. Methods: A total of 163 patients with colorectal cancer who received surgical treatment in our hospital from April 2020 to April 2023 were selected as the colorectal cancer group and 93patients with colorectal polyp group as the control group. By comparing the differences of lymphocyte/C-reactive protein ratio (LCR), C-reactive protein/albumin ratio (CAR), CA199 and CEA in the two groups, correlation analysis was performed with clinicopathological features, and the detection efficiency results were plotted by ROC curve. Results: The expressions of CAR, CEA and CA199 were significantly increased in colorectal cancer group, while the expressions of LCR were decreased, with statistical differences among all groups (P < 0.001). The expression of LCR in the depth of tumor invasion (T3 + T4) group was significantly lower than that in the (T1 + T2) group, the expression of LCR was decreased in the group with lymph node metastasis, and the expression of TNM staging (III + IV) was significantly lower than that in the (I + II) group, with statistical differences among all groups. The expressions of CAR, CEA and CA199 were opposite to those of LCR, and there were statistical differences among all groups (P < 0.05). The ROC curve indicated that the sensitivity and specificity of combined diagnosis were 55.2% and 90.3%. Conclusions: The levels of LCR, CAR, CA199 and CEA are correlated with the clinicopathologic characteristics of patients with colorectal cancer, and have potential value in the diagnosis of colorectal cancer. Combined detection can improve the sensitivity of the diagnosis of colorectal cancer.
文章引用:苏友玉, 徐大方, 石茜, 强锋, 郑思洋, 胡洁. 基于C反应蛋白新炎症因子组合在结直肠癌诊断中的临床价值[J]. 临床医学进展, 2025, 15(9): 375-384. https://doi.org/10.12677/acm.2025.1592501

1. 引言

结直肠癌在全球范围内位列发病率排名第3位,死亡率第2位[1]。虽然诊断技术和治疗方案不断地改善,但死亡率仍然很高。目前结直肠癌的筛查缺乏简便,廉价而又特异性较高且依从性较好的指标。从而导致早期发现,较为困难,而肿瘤的分期仍然是影响预后的主要原因之一,为了早期发现结直肠癌,提高生存效率,寻找有效的预测指标尤为重要。

血液分成与肿瘤直接接触,也与肿瘤微环境相关。血液中的相关组分与肿瘤关系密切。癌胚抗原(carcino-embryonic antigen CEA)作为血液中常见的胃肠道肿瘤的指标,被用来预测消化道肿瘤包括结直肠癌的诊断,预后。糖类抗原199 (carbohydrate antigen 199 CA199)作为细胞表面的糖蛋白,能够被多种肿瘤细胞分泌,同样被用来作为常用肿瘤标志物。但不同学者对于其诊断特异性,敏感性存在争议,故仍需要探索更多血液的标志物用来早期诊断结直肠癌[2]

越来越多的证据证明,全身的炎症感染与宿主之间的反应被认为是癌症的第7大特征,涉及到肿瘤的发生发展及预后[3]。基于这些知识的积累,研究表明潜在的炎症标志物,比如C-反应蛋白(C-reactive protein CRP),白蛋白,淋巴细胞,中性粒细胞及相应的比例组合,均可能成为包括结直肠癌在内的许多肿瘤的预测标志物[4]

本文通过回顾分析病历资料,计算淋巴细胞与C反应蛋白比值(lymphocyte/C-reactive protein ratio LCR),C反应蛋白与白蛋白比值(C-reactive protein/albumin ratio CAR),结合常用肿瘤标志物CEA、CA199数值,通过比较指标在结肠息肉与术后病理确诊结直肠癌组中的差异表达,与临床病理特征进行分析,并构建受试者特征曲线(Receiver Operating Characteristic Curve ROC),获得结直肠癌的预测效率,意在提高早期诊断结直肠癌。

2. 资料与方法

2.1. 一般资料

回顾性选择2020年04月至2023年04月在本院行手术切除的在档结直肠癌患者163例,所有切除标本均经术后病理诊断明确。其中男性101例,女性62例,年龄28~88岁,中位年龄67 (60, 73)岁,结肠癌82例,直肠癌81例。纳入标准:1、年龄 > 18周岁。2、术后病理确诊结直肠癌。3、留存资料完整。排除标准:1、入院前2周发现其他肿瘤患者。2、术前新辅助化疗。3、术前6周有输血史。4、有远处转移无法切除。5、术前相关辅助检查资料不完整。同时采纳同期住院健康体检无明显症状,且肠镜检查发现结肠息肉住院病人,无其他明显基础疾病,共93例,为对照组,其中男性57例,女性36例。年龄35~77岁,中位年龄66 (62, 69)岁,两组之间患者年龄,性别未见明显统计学差异(P > 0.05)。本研究遵循医学研究相关原则,获得湖州市第一人民医院伦理委员会批准(审批号:伦第2019038号)

2.2. 方法

收集患者入院后第一次常规静脉采血记录的相应检测值,包括CEA、CA199,血常规中的淋巴细胞计数,生化检查中C反应蛋白(CRP)检测值,白蛋白(albumin ALB)值作为分析对象。LCR比值 = 淋巴细胞计数/C反应蛋白比值,CAR比值 = C反应蛋白/白蛋白比值。通过构建ROC曲线明确相应指标的截断值(cut-off),通过计算获得约登指数(Youden index)。

2.3. 统计方法

采用SPSS25.0统计软件处理相应数据。所有数据均进行正态性检验,采用(Shapiro-wilk, SK)分析,P > 0.05为符合正态分布。非正态分布计量数据采用[M(P25, P75)]表示,组间采用Wilcoxon秩和检验。P < 0.05设置为有统计学差异。

3. 结果

3.1. 两组之间LCR、CAR、CEA、CA199水平比较

Table 1. Comparison of LCR, CAR, CEA, CA199 levels between two groups [M(P25, P75)]

1. 两组间LCR、CAR、CEA、CA199水平比较[M(P25, P75)]

分组

例数

LCR

CAR

CEA

CA199

结直肠息肉组

93

1.33 (0.68, 2.67)

0.02 (0.01, 0.05)

2.16 (1.64, 3.29)

4.1 (2.8, 8.6)

结直肠癌组

163

0.77 (0.22, 1.44)

0.04 (0.02, 0.14)

4.1 (2.36, 8.81)

6.6 (3.1, 18.2)

Z

−4.27

−4.0

−6.706

−3.204

P

P < 0.001

P < 0.001

P < 0.001

0.002

经过秩和检验分析,发现CAR、CEA、CA199在结直肠癌组中表达明显高于结直肠息肉组,LCR在结直肠癌组中表达低于结直肠息肉组,两组数据均存在统计学差异(P < 0.05),见表1

3.2. LCR、CAR、CEA、CA199分别与术后病理特征相关性分析

通过分析发现LCR及CAR在肿瘤位置中存在差异性表达,LCR在结肠癌中表达更低,两组存在差异性,具有统计学意义(P = 0.016);CAR在直肠癌中表达更低,两组存在差异性,具有统计学意义(P = 0.017)。而CEA、CA199在肿瘤位置中无统计学差异表达(P > 0.05)。在性别差异及有无远处转移的分组比较中,所分析的四个指标里,仅癌胚抗原(CEA)的差异具有统计学意义(P = 0.019),其余三个指标的组间差异均无统计学意义(P > 0.05)。相应结果显示,LCR在肿瘤浸润深度(T3 + T4)组表达明显低于(T1 + T2)组,存在阳性淋巴结组表达降低,TNM分期为(III + IV)表达明显低于(I + II)组,各组之间均存在统计学差异。提示LCR表达降低与肿瘤进展相关。而CAR、CEA、CA199表达在肿瘤浸润深度(T3 + T4)与(T1 + T2)组相比,数值明显上升,淋巴结阳性组数值升高,TNM分期(III + IV)表达明显高于(I + II)组,统计学角度分析,各组之间差异均有意义(P < 0.05)。见表2~5

Table 2. Analysis of the association between the Lymphocyte-to-C-Reactive Protein Ratio (LCR) and clinicopathological features in colorectal cancer

2. 淋巴细胞计数/C-反应蛋白比值(LCR)与结直肠癌临床病理特征关系分析

变量

例数

LCR

Z

P

[M(P25, P75)]

性别

101

0.81 (0.21, 1.4)

−0.133

0.894

62

0.74 (0.24, 1.50)

肿瘤位置

结肠

82

0.66 (0.15, 1.34)

−2.405

0.016

直肠

81

0.92 (0.44, 1.65)

肿瘤浸润程度

T1 + T2

49

1.37 (0.72, 2.79)

−4.459

P < 0.001

T3 + T4

114

0.64 (0.18, 1.2)

淋巴结转移

64

0.5 (0.17, 1.04)

−3.220

0.001

99

1.05 (0.36, 1.64)

远处转移

9

0.65 (0.29, 1.07)

−0.581

0.561

154

0.81 (0.22, 1.47)

TNM分期

I + II期

97

1.07 (0.36, 1.65)

−3.213

0.001

III + IV期

66

0.52 (0.18, 1.02)

Table 3. Analysis of the association between the C-Reactive Protein-to-Albumin Ratio (CAR) and clinicopathological features in colorectal cancer

3. C反应蛋白/白蛋白比值(CAR)与结直肠癌临床病理特征关系分析

变量

例数

CAR

Z

P

[M(P25, P75)]

性别

101

0.04 (0.02, 0.13)

−0.14

0.891

62

0.05 (0.02, 0.19)

肿瘤位置

结肠

82

0.07 (0.03, 0.27)

−2.38

0.017

直肠

81

0.04 (0.02, 0.09)

肿瘤浸润程度

T1 + T2

49

0.03 (0.01, 0.04)

−4.584

P < 0.001

T3 + T4

114

0.07 (0.03, 0.26)

淋巴结转移

64

0.08 (0.03, 0.26)

−2.806

0.005

99

0.04 (0.02, 0.09)

远处转移

9

0.08 (0.04, 0.15)

−0.861

0.389

154

0.04 (0.02, 0.14)

TNM分期

I + II期

97

0.04 (0.02, 0.09)

−2.884

0.004

III + IV期

66

0.08 (0.03, 0.25)

Table 4. Analysis of the association between carcinoembryonic antigen (CEA) and clinicopathological features in colorectal cancer

4. 癌胚抗原(CEA)与结直肠癌临床病理特征关系分析

变量

例数

CEA

Z

P

[M(P25, P75)]

性别

101

4.5 (3.08, 8.73)

−1.716

0.086

62

3.6 (1.99, 11.28)

肿瘤位置

结肠

82

4.7 (2.26, 11.49)

−0.561

0.575

直肠

81

3.8 (2.5, 8.41)

肿瘤浸润程度

T1 + T2

49

3.28 (2.03, 4.47)

−3.815

P < 0.001

T3 + T4

114

4.87 (2.84, 12.31)

淋巴结转移

64

5.58 (3.27, 23.04)

−3.546

P < 0.001

99

3.62 (2.16, 5.87)

远处转移

9

11.15 (4.0, 95.25)

−2.34

0.019

154

4.01 (2.3, 8.37)

TNM分期

I + II期

97

3.61 (2.12, 5.62)

−4.021

P < 0.001

III + IV期

66

5.73 (3.43, 25.95)

Table 5. Analysis of the association between Carbohydrate Antigen 199 (CA199) and clinicopathological features in colorectal cancer

5. 糖类抗原199 (CA199)与结直肠癌临床病理特征关系分析

变量

例数

CA199

Z

P

[M(P25, P75)]

性别

101

7 (3.05, 18)

−0.430

0.667

62

6.3 (2.99, 20.9)

肿瘤位置

结肠

82

7.15 (3.08, 18.87)

−0.667

0.505

直肠

81

5.9 (3.05, 18.35)

肿瘤浸润程度

T1 + T2

49

5 (2.6, 12.05)

−2.118

0.034

T3 + T4

114

7.25 (3.3, 22.68)

淋巴结转移

64

11.35 (4.12, 37.3)

−2.955

0.003

99

5.8 (2.6, 13.12)

远处转移

9

11.4 (5.65, 46.44)

−1.474

0.14

154

6.45 (2.97, 18.2)

TNM分期

I + II期

97

5.8 (2.6, 12.76)

−3.243

0.001

III + IV期

66

11.65 (4.18, 37.7)

3.3. LCR、CAR、CEA、CA199分别及综合检测对结直肠癌的诊断效率

利用ROC曲线绘制,分析结直肠癌组与结直肠息肉组诊断效率,获得LCR、CAR、CA199、CEA分别截断值为0.649,0.023,4.65,2.92。对应的约登指数分别为0.255,0.254,0.214,0.414。LCR、CAR、CA199、CEA独自诊断结直肠癌的AUC曲线下面积分别为0.660,0.650,0.615,0.752,见图1。四者联合诊断AUC做高为0.782 (P < 0.001)。单独诊断的灵敏度分别为67.5%,73.6%,64.4%,69.3%,特异性分别为58.1%,51.6%,58.1%,72%。而联合诊断敏感度为56.4%,特异性为90.3%。整体检测效率较好。见表6

Table 6. Diagnostic efficiency of individual and combined detection of LCR, CAR, CEA, and CA199 in colorectal cancer

6. LCR、CAR、CEA、CA199分别及联合检测对结直肠癌的诊断效率

变量

线下面积

P值

95%可信区间

约登指数

截断值

敏感性

特异性

LCR

0.660

P < 0.001

0.593~0.728

0.255

0.649

67.5

58.1

CAR

0.650

P < 0.001

0.582~0.718

0.254

0.023

73.6

51.6

CA199

0.615

0.002

0.552~0.688

0.214

4.6

64.4

58.1

CEA

0.752

P < 0.001

0.693~0.811

0.414

2.92

69.3

72

Combined

0.782

P < 0.001

0.728~0.837

0.467

0.688

56.4

90.3

Figure 1. ROC analysis of individual and combined detection of LCR, CAR, CEA, and CA199 in colorectal cancer

1. LCR、CAR、CEA、CA199单独及联合检测ROC分析

4. 讨论

本文回顾性地分析了基于163例行手术切除的结直肠癌患者术前数据,对照93例结直肠良性息肉健康体检者,表明LCR、CAR、CA199及CEA单独及联合检测对结直肠癌的预测价值。虽然这些指标在许多肿瘤中被报道具有预测价值,但利用外周血最佳的联合指标检测,尚缺乏统一观点,目前尚未见四者在结直肠癌中联合检测的报道。本文结果发现与对照组相比,CAR、CA199及CEA表达明显高于对照组,LCR明显低于对照组,存在统计学差异,通过与术后病理特征分析,四个指标均与肿瘤的浸润深度,淋巴结转移,TNM转移相关,提示与结直肠癌的进展有密切关系。而ROC曲线提示四者联合检测提高了诊断效率,提示多项指标的改变,更加有助于结直肠癌的诊断。

LCR是淋巴细胞与CRP的比值,外周血淋巴细胞是肿瘤患者免疫相关的重要角色,也是被用来评估患者身体状况的主要指标之一。而CRP是作为常用的炎症指标代表,体现机体对炎症刺激的急性反应[5]。多项回顾性的研究发现,CRP的升高与结直肠癌不良预后相关[6]-[8]。Murat Y等对57例结直肠癌患者研究发现LCR是预测术后早期并发症的新指标,有很好的预测价值[9]。Yoshinaga Okugawa等通过对477例结肠癌患者LCR的测定发现LCR是围手术期并发症评估的重要指标,并与预后相关[4]。Ou等人分析955例结直肠癌患者LCR对肿瘤相关生存及总生存率相关性,并通过ROC曲线确定最佳预测阈值,发现低LCR与患者的病理特征相关,与肿瘤浸润有关,提示更差的预后[10]。本文结果提示与对照组相比,LCR的比值明显降低,存在统计学的差异(P < 0.001)。临床病理特征分析,与既往研究一致,更低的LCR值与肿瘤浸润深度,淋巴结转移,TNM期相关,提示LCR低表达与结直肠癌恶性进展相关,与文献报道一致[11]。ROC曲线提示LCR的预测阈值为0.649,约登指数0.256。敏感性67.5%,特异性58.1%,提示单个指标存在一定的预测价值。

术前血液中的CRP和白蛋白(ALB)的表达量分别代表了炎症和营养的状况。Glasgow预后评分(GPS)可以评估许多肿瘤的状态,采用CRP和白蛋白的含量作为评分标准[12]。ZÁHOREC等通过对比145例结直肠癌患者对比42例结直肠良性病变,分析了术前CRP,ALB及淋巴细胞的表达,后发现ALB有助于区别结直肠良恶性病变[13]。但后来Chen和Kinoshita等研究发现CAR与单纯CRP和白蛋白的含量相比,更适合作为预测指标[14] [15]。Masaaki M等在胰腺癌中发现CAR比值与肿瘤病理特征,预后相关,最佳阈值为 > 0.036 [16]。Masahide I等学者通过对局部进展期结直肠癌的外周血CAR的分析,发现高标表达CAR (阈值 > 0.65),患者的远处转移增加,两年的总生存期明显地降低[17]

本文结果显示与对照组相比,CAR比值明显增高,两组区别明显存在统计学差异,且CAR增高与肿瘤浸润深度,有淋巴结转移,TNM分期越晚有关,提示CAR增高不但可以提示结直肠癌可能,同时高表达与恶性进展相关。ROC曲线提示最佳阈值为0.023,敏感性73.6%,特异性为51.6%,有一定的预测价值。

CEA是结直肠癌的一个经典的肿瘤标志物,在肿瘤的诊断,监测,预后均有关键的作用[18]。但是单个的CEA结果在预测结果中,仍然存在着局限性,学者Gunawardene发现单独使用CEA预测总的生存率,AUC曲线下0.62,阈值 < 3.3 ng/mL [19]。Kim等利用CEA预测根治性的切除后,II期的患者无复发生存期(RFS) AUC曲线下面积,得出与Gunawardene等研究结论一致[20]。Jiang等通过分析横结肠癌发现术前CA199表达与总体生存率(0S)和无病生存期(DFS)相关,是一个重要的预测指标[21]。Wu等通过比较结直肠癌患者与健康体检者血清中CEA与CA199的表达,发现联合检测可以增加结直肠癌的诊断效率,弥补单个指标的敏感性与特异性不足的缺点[22]。笔者同样分析了CEA和CA199的表达,与对照组相比,明显增高,统计学差异明显,与其他指标一致,病理特征中,与浸润深度,淋巴结转移,TNM分期相关,趋势与既往研究结论基本符合,虽然ROC曲线提示CEA有较好的诊断阈值,但特异性一般,CA199诊断阈值一般,敏感性较高,但特异性较差。

我们使用ROC曲线绘制,验证四组指标联合检测后的作用,结果证明合并检测可以提高诊断的准确性,阳性率更高。提示联合检测能够更好地发挥预测作用。

本研究存在一定局限性,如本文中的四个指标,在研究中,均未发现与患者性别相关,而与其他研究稍有区别,与远处转移亦无相关性,可能与远处肝转移病例数较少有关;本研究部分患者在出现症状后就诊,此时肿瘤分期可能已较晚,导致病例组中肿瘤分期分布与实际临床情况存在偏差,可能因此导致LCR与CAR的诊断效能出现偏差。未来研究可优化入组策略,纳入包括早期无症状阶段在内的不同疾病截断患者,减少选择偏倚的影响,更客观全面地评估LCR和CAR的诊断效能。

综上所述,我们的研究结果提示LCR、CAR、CA199、CEA在结直肠癌与良性病变组存在表达差异,并与结直肠癌的病理特征密切相关。联合检测可以提高结直肠癌的早期诊断的灵敏度。

基金项目

浙江省基础公益研究资助项目“基于裸鼠结直肠癌模型研究新型长链非编码RNA-RP11-296E3.2介导miR-34α调控肿瘤转移机制”编号(LGD20H030001)。

NOTES

*通讯作者。

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
[2] Machado Carvalho, J.V., Dutoit, V., Corrò, C. and Koessler, T. (2023) Promises and Challenges of Predictive Blood Biomarkers for Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. Cells, 12, Article No. 413.
https://doi.org/10.3390/cells12030413
[3] Song, X.D., Wang, Y.N., Zhang, A.L. and Liu, B. (2019) Advances in Research on the Interaction between Inflammation and Cancer. Journal of International Medical Research, 48, 1473-2300.
https://doi.org/10.1177/0300060519895347
[4] Okugawa, Y., Toiyama, Y., Yamamoto, A., Shigemori, T., Ide, S., Kitajima, T., et al. (2019) Lymphocyte-c-Reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Annals of Surgery, 272, 342-351.
https://doi.org/10.1097/sla.0000000000003239
[5] Miyatani, K., Sawata, S., Makinoya, M., Miyauchi, W., Shimizu, S., Shishido, Y., et al. (2022) Combined Analysis of Preoperative and Postoperative Lymphocyte-C-Reactive Protein Ratio Precisely Predicts Outcomes of Patients with Gastric Cancer. BMC Cancer, 22, Article No. 641.
https://doi.org/10.1186/s12885-022-09716-9
[6] Yamamoto, M., Saito, H., Uejima, C., Tanio, A., Takaya, S., Sakamoto, T., et al. (2018) Prognostic Value of the Combination of Pre-and Postoperative C-Reactive Protein in Colorectal Cancer Patients. Surgery Today, 48, 986-993.
https://doi.org/10.1007/s00595-018-1689-9
[7] Holm, M., Saraswat, M., Joenväärä, S., Ristimäki, A., Haglund, C. and Renkonen, R. (2018) Colorectal Cancer Patients with Different C-Reactive Protein Levels and 5-Year Survival Times Can Be Differentiated with Quantitative Serum Proteomics. PLOS ONE, 13, e0195354.
https://doi.org/10.1371/journal.pone.0195354
[8] Aires, F., Rodrigues, D., Lamas, M.P., Herdeiro, M.T., Figueiras, A., Oliveira, M.J., et al. (2022) C-reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study. Cancers, 14, Article No. 491.
https://doi.org/10.3390/cancers14030491
[9] Yildirim, M. and Koca, B. (2021) Lymphocyte C-Reactive Protein Ratio: A New Biomarker to Predict Early Complications after Gastrointestinal Oncologic Surgery. Cancer Biomarkers, 31, 409-417.
https://doi.org/10.3233/cbm-210251
[10] Ou, W., Zhou, C., Zhu, X., Lin, L. and Xu, Q. (2021) Prognostic Significance of Preoperative Lymphocyte-to-C-Reactive Protein Ratio in Patients with Non-Metastatic Colorectal Cancer. OncoTargets and Therapy, 14, 337-346.
https://doi.org/10.2147/ott.s290234
[11] 曾凡鹏, 路庆艳, 李青. 术前HRP、LCR和CEA水平在结直肠癌中的临床价值分析[J]. 国际检验医学杂志, 2022, 43(7): 818-822.
[12] Tsuzuki, S., Kimura, S., Fukuokaya, W., Yanagisawa, T., Hata, K., Miki, J., et al. (2020) Modified Glasgow Prognostic Score Is a Pre-Surgical Prognostic Marker of Disease Mortality in Upper Urinary Tract Urothelial Carcinoma. Japanese Journal of Clinical Oncology, 51, 138-144.
https://doi.org/10.1093/jjco/hyaa133
[13] Záhorec, R., Marek, V., Waczulíková, I., Veselovský, T., Palaj, J., Kečkéš, Š., et al. (2021) Predictive Model Using Hemoglobin, Albumin, Fibrinogen, and Neutrophil-to-Lymphocyte Ratio to Distinguish Patients with Colorectal Cancer from Those with Benign Adenoma. Neoplasma, 68, 1292-1300.
https://doi.org/10.4149/neo_2021_210331n435
[14] Konishi, S., Hatakeyama, S., Tanaka, T., Ikehata, Y., Tanaka, T., Hamano, I., et al. (2019) Prognostic Significance of Preoperative C‐Reactive Protein/Albumin Ratio Is a Predictive Factor for Prognosis in Patients with Metastatic Renal Cell Carcinoma. International Journal of Urology, 26, 992-998.
https://doi.org/10.1111/iju.14078
[15] Liu, Z., Chen, L., Sun, F., Lv, B., Ge, X., Shao, L., et al. (2022) C-Reactive Protein/Albumin Ratio on the First Day after Surgery Predicts Short-Term Complications of Gastrectomy for Gastric Cancer. Nutrition and Cancer, 74, 3574-3581.
https://doi.org/10.1080/01635581.2022.2083190
[16] Murakawa, M., Yamamoto, N., Kamioka, Y., Kamiya, M., Kobayashi, S., Ueno, M., et al. (2019) Clinical Implication of Pre-Operative C-Reactive Protein-Albumin Ratio as a Prognostic Factor of Patients with Pancreatic Ductal Adenocarcinoma: A Single-Institutional Retrospective Study. In Vivo, 34, 347-353.
https://doi.org/10.21873/invivo.11780
[17] Ikeguchi, M. and Ashida, K. (2017) Prognostic Significance of C-Reactive Protein/Albumin Ratio in Patients with Locally Advanced Unresectable Colorectal Cancer. Indian Journal of Surgical Oncology, 8, 263-266.
https://doi.org/10.1007/s13193-017-0639-0
[18] Zhou, Y., Cheng, F., Zhang, Z., Xiang, J., Xue, T., Ye, Q., et al. (2022) Preoperative Absolute Lymphocyte Count to Carcinoembryonic Antigen Ratio Is a Superior Predictor of Survival in Stage I to III Colorectal Cancer. Clinical Medicine Insights: Oncology, 16, 1-10.
https://doi.org/10.1177/11795549221126249
[19] Gunawardene, A., Larsen, P., Shekouh, A. and Dennett, E. (2018) Pre‐Operative Carcinoembryonic Antigen Predicts Survival Following Colorectal Cancer Surgery with Curative Intent. ANZ Journal of Surgery, 88, 1311-1315.
https://doi.org/10.1111/ans.14723
[20] Kim, H., Kim, H.S., Yang, S.Y., Han, Y.D., Cho, M.S., Hur, H., et al. (2021) Early Recurrence after Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: Characteristics and Risk Factors. Asian Journal of Surgery, 44, 298-302.
https://doi.org/10.1016/j.asjsur.2020.07.014
[21] Jiang, Y., Zou, Z., Zhang, Z., Zhang, Y., Sun, Y. and Liang, B. (2020) Long-Term Outcomes of Radical Surgery for Transverse Colon Cancer Staged from I to IIIC. Cancer Management and Research, 12, 13043-13049.
https://doi.org/10.2147/cmar.s244777
[22] Wu, J., Wu, M. and Wu, Q. (2020) Identification of Potential Metabolite Markers for Colon Cancer and Rectal Cancer Using Serum Metabolomics. Journal of Clinical Laboratory Analysis, 34, 1-7.
https://doi.org/10.1002/jcla.23333